Stock DNA
Pharmaceuticals & Biotechnology
INR 67 Cr (Micro Cap)
NA (Loss Making)
40
0.00%
0.15
-1.70%
0.96
Total Returns (Price + Dividend) 
Latest dividend: 1 per share ex-dividend date: Sep-18-2025
Risk Adjusted Returns v/s 
Returns Beta
News

Samrat Pharmachem Ltd is Rated Sell
Samrat Pharmachem Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 October 2026, providing investors with the latest insights into its performance and outlook.
Read More
Samrat Pharmachem Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals
Samrat Pharmachem Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 14 Oct 2026, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The company’s micro-cap status and challenging financial trends continue to weigh on its outlook, but recent technical signals suggest a cautiously improved market sentiment.
Read More
Samrat Pharmachem Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Technical Setbacks
Samrat Pharmachem Ltd has been downgraded from a Sell to a Strong Sell rating as of 09 Oct 2026, reflecting deteriorating technical indicators and weak fundamental performance. The pharmaceutical micro-cap’s Mojo Score has declined to 23.0, signalling heightened risk for investors amid flat financial results and a challenging market environment.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
18-Nov-2026 | Source : BSENewspaper Publication of extract of Standalone Unaudited Financial Results for the quarter ended 30th September 2026
Board Meeting Outcome for Outcome Of Board Meeting Held On 14Th November 2026
14-Nov-2026 | Source : BSEThe Board of Directors considered and adopted the unaudited financial results for the quarter ended September 30 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
13-Oct-2026 | Source : BSECertificate under Reg. 74(5) of SEBI (DP) Regulations for the quarter ended 30th September 2026.
Corporate Actions 
No Upcoming Board Meetings
Samrat Pharmachem Ltd has declared 10% dividend, ex-date: 18 Sep 25
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Lalit Damodar Mehta (13.97%)
Sangeetha S (3.27%)
41.79%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is -17.24% vs 11.13% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -50.00% vs 143.14% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 2.33% vs 10.04% in Sep 2024
Growth in half year ended Sep 2025 is -117.34% vs 1,026.19% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 1.53% vs 7.93% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -117.04% vs 888.16% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 1.35% vs 1.52% in Mar 2025
YoY Growth in year ended Mar 2026 is -146.55% vs 229.17% in Mar 2025